Published in Proc Natl Acad Sci U S A on January 31, 1995
The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc Natl Acad Sci U S A (1996) 2.58
Hypoxia induces severe right ventricular dilatation and infarction in heme oxygenase-1 null mice. J Clin Invest (1999) 2.44
A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J Clin Invest (1998) 2.08
Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiator of blood coagulation. Proc Natl Acad Sci U S A (1996) 1.93
Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice. J Clin Invest (1998) 1.55
Laser-induced noninvasive vascular injury models in mice generate platelet- and coagulation-dependent thrombi. Am J Pathol (2001) 1.48
Complete antithrombin deficiency in mice results in embryonic lethality. J Clin Invest (2000) 1.44
The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications. Blood (2009) 1.21
Endothelium-specific loss of murine thrombomodulin disrupts the protein C anticoagulant pathway and causes juvenile-onset thrombosis. J Clin Invest (2001) 1.20
Down-regulation of endothelial expression of endothelial cell protein C receptor and thrombomodulin in coronary atherosclerosis. Am J Pathol (2001) 1.19
Tissue factor expression during human and mouse development. Am J Pathol (1996) 1.19
Mice with a severe deficiency in protein C display prothrombotic and proinflammatory phenotypes and compromised maternal reproductive capabilities. J Clin Invest (2005) 1.17
Fetomaternal cross talk in the placental vascular bed: control of coagulation by trophoblast cells. Blood (2005) 1.05
Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domain. Blood (2011) 1.00
Simvastatin ameliorates radiation enteropathy development after localized, fractionated irradiation by a protein C-independent mechanism. Int J Radiat Oncol Biol Phys (2007) 0.99
Thrombomodulin modulates growth of tumor cells independent of its anticoagulant activity. J Clin Invest (1998) 0.95
Downregulation of thrombomodulin, a novel target of Snail, induces tumorigenesis through epithelial-mesenchymal transition. Mol Cell Biol (2010) 0.88
Thrombomodulin: a bifunctional modulator of inflammation and coagulation in sepsis. Crit Care Res Pract (2012) 0.85
Expression of thrombomodulin and consequences of thrombomodulin deficiency during healing of cutaneous wounds. Am J Pathol (1999) 0.84
Heparan sulfate: antithrombotic or not? J Clin Invest (2003) 0.84
Exacerbation of oxidative stress-induced cell death and differentiation in induced pluripotent stem cells lacking heme oxygenase-1. Stem Cells Dev (2011) 0.83
An accompanying genetic severe deficiency of tissue factor protects mice with a protein C deficiency from lethal endotoxemia. Blood (2010) 0.81
Maternal Par4 and platelets contribute to defective placenta formation in mouse embryos lacking thrombomodulin. Blood (2008) 0.79
Mycolactone-Dependent Depletion of Endothelial Cell Thrombomodulin Is Strongly Associated with Fibrin Deposition in Buruli Ulcer Lesions. PLoS Pathog (2015) 0.78
Human thrombomodulin knock-in mice reveal differential effects of human thrombomodulin on thrombosis and atherosclerosis. Arterioscler Thromb Vasc Biol (2011) 0.76
A thrombomodulin mutation that impairs active protein C generation is detrimental in severe pneumonia-derived gram-negative sepsis (melioidosis). PLoS Negl Trop Dis (2014) 0.76
Localization of thrombomodulin in pericryptal fibroblasts of the rat duodenum. Histochem Cell Biol (2004) 0.75
Thrombomodulin promotes focal adhesion kinase activation and contributes to angiogenesis by binding to fibronectin. Oncotarget (2016) 0.75
KLF2 and KLF4 control endothelial identity and vascular integrity. JCI Insight (2017) 0.75
Variable phenotypic penetrance of thrombosis in adult mice after tissue-selective and temporally controlled Thbd gene inactivation. Blood Adv (2017) 0.75
Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature (1994) 9.06
Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Development (1993) 6.56
Physiological consequences of loss of plasminogen activator gene function in mice. Nature (1994) 4.40
The regulation of natural anticoagulant pathways. Science (1987) 2.58
Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med (1987) 1.79
Isolation and characterization of thrombomodulin from human placenta. J Biol Chem (1984) 1.50
Disparate temporal expression of the prothrombin and thrombin receptor genes during mouse development. Am J Pathol (1994) 1.35
The clinical spectrum of heterozygous protein C deficiency in a large New England kindred. Blood (1989) 1.26
Identification of fetomodulin, a surface marker protein of fetal development, as thrombomodulin by gene cloning and functional assays. Dev Biol (1990) 1.18
Equilibrium binding of thrombin to recombinant human thrombomodulin: effect of hirudin, fibrinogen, factor Va, and peptide analogues. Biochemistry (1990) 1.15
Hyaluronate degradation affects ventricular function of the early postlooped embryonic rat heart in situ. Circ Res (1994) 1.11
Ultrastructure of Reichert's membrane, a multilayered basement membrane in the parietal wall of the rat yolk sac. J Cell Biol (1983) 1.06
Quantitation of a murine lung endothelial cell protein, P112, with a double monoclonal antibody assay. Lab Invest (1988) 1.06
Preservation of thrombomodulin antigen on vascular and extravascular surfaces. J Histochem Cytochem (1987) 0.97
Embryotoxic effects of heterologous antisera against rat Reichert's membrane. J Exp Zool (1977) 0.89
The permeability of the guinea pig parietal yolk sac placenta to peroxidase and ferritin. Am J Anat (1972) 0.85
Improved growth and development of presomite mouse embryos in whole embryo culture. J Exp Zool (1988) 0.84
An intracisternal A-particle DNA sequence is closely linked to the thrombomodulin gene in some strains of laboratory mice. DNA Cell Biol (1993) 0.82
Breast Cancer Surveillance Consortium: a national mammography screening and outcomes database. AJR Am J Roentgenol (1997) 7.62
A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. Cell (1999) 6.82
Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA (2005) 5.60
Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med (1999) 4.44
The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem (1973) 4.24
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
The separation of active and inactive forms of heparin. Biochem Biophys Res Commun (1976) 2.91
Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med (1990) 2.82
Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature (1992) 2.73
Benefits versus risks from mammography: a critical reassessment. Cancer (1996) 2.43
Anticoagulant action of heparin. Nature (1973) 2.26
Isolation of a src homology 2-containing tyrosine phosphatase. Proc Natl Acad Sci U S A (1992) 2.22
A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J Clin Invest (1998) 2.08
Actions and interactions of antithrombin and heparin. N Engl J Med (1975) 2.06
Current medicolegal and confidentiality issues in large, multicenter research programs. Am J Epidemiol (2000) 2.06
Cloned bovine aortic endothelial cells synthesize anticoagulantly active heparan sulfate proteoglycan. J Biol Chem (1986) 2.02
Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin. Circ Res (1980) 2.00
Inhibition of vascular smooth muscle cell growth by endothelial cell-derived heparin. Possible role of a platelet endoglycosidase. J Biol Chem (1982) 1.99
Isolation and characterization of endothelial progenitor cells from mouse embryos. Development (1998) 1.94
Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J Thromb Haemost (2004) 1.91
Mast cell clones: a model for the analysis of cellular maturation. J Cell Biol (1982) 1.91
PR39, a peptide regulator of angiogenesis. Nat Med (2000) 1.90
Contribution of monosaccharide residues in heparin binding to antithrombin III. Biochemistry (1985) 1.89
Chemistry of the hemostatic mechanism and its relationship to the action of heparin. Fed Proc (1977) 1.83
Correlation between structure and function of heparin. Proc Natl Acad Sci U S A (1979) 1.83
An antiproliferative heparan sulfate species produced by postconfluent smooth muscle cells. J Cell Biol (1985) 1.83
Molecular heterogeneity of inherited antithrombin III deficiency. N Engl J Med (1983) 1.75
Natural anticoagulant mechanisms. J Clin Invest (1984) 1.75
Vascular bed-specific expression of an endothelial cell gene is programmed by the tissue microenvironment. J Cell Biol (1997) 1.74
Anticoagulantly active heparin-like molecules from vascular tissue. Biochemistry (1984) 1.70
Structure-function relationships of heparin species. Proc Natl Acad Sci U S A (1978) 1.65
Expression of heparan sulfate D-glucosaminyl 3-O-sulfotransferase isoforms reveals novel substrate specificities. J Biol Chem (1999) 1.58
Multiple isoforms of heparan sulfate D-glucosaminyl 3-O-sulfotransferase. Isolation, characterization, and expression of human cdnas and identification of distinct genomic loci. J Biol Chem (1999) 1.58
Spontaneous thrombosis in mice carrying the factor V Leiden mutation. Blood (2000) 1.58
Heparinlike molecules with anticoagulant activity are synthesized by cultured endothelial cells. Biochem Biophys Res Commun (1985) 1.56
Inhibition of activated factor XII by antithrombin-heparin cofactor. J Biol Chem (1976) 1.56
Treatment of coumarin-induced skin necrosis with a monoclonal antibody purified protein C concentrate. Arch Dermatol (1993) 1.55
Enzymatic modification of heparan sulfate on a biochip promotes its interaction with antithrombin III. Biochem Biophys Res Commun (2000) 1.51
Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest (1994) 1.50
Acceleration of thrombin-antithrombin complex formation in rat hindquarters via heparinlike molecules bound to the endothelium. J Clin Invest (1984) 1.48
Haemostatic changes that constitute the hypercoagulable state. Lancet (1991) 1.47
The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin. J Biol Chem (1980) 1.47
Isolation and characterization of heparin from human lung. J Clin Invest (1979) 1.46
Heparan sulfate D-glucosaminyl 3-O-sulfotransferase-3A sulfates N-unsubstituted glucosamine residues. J Biol Chem (1999) 1.45
Multiple functional domains of the heparin molecule. Proc Natl Acad Sci U S A (1981) 1.45
Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol (1988) 1.44
Purification and properties of human platelet heparitinase. J Biol Chem (1982) 1.42
Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest (1980) 1.42
Molecular cloning and expression of two distinct cDNA-encoding heparan sulfate proteoglycan core proteins from a rat endothelial cell line. J Biol Chem (1992) 1.41
Localization of anticoagulantly active heparan sulfate proteoglycans in vascular endothelium: antithrombin binding on cultured endothelial cells and perfused rat aorta. J Cell Biol (1990) 1.40
Biologic actions of heparin. Semin Hematol (1977) 1.38
Genetic and ultrastructural characterization of a European isolate of the fatal endotheliotropic elephant herpesvirus. J Gen Virol (2001) 1.37
The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci U S A (1994) 1.36
The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood (1995) 1.35
Microvascular heparin-like species with anticoagulant activity. Am J Physiol (1983) 1.34
Binding of lipoprotein lipase to endothelial cells in culture. J Biol Chem (1981) 1.31
The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation. Blood (1987) 1.31
Molecular cloning and expression of mouse and human cDNAs encoding heparan sulfate D-glucosaminyl 3-O-sulfotransferase. J Biol Chem (1997) 1.30
Improvement in mammography interpretation skills in a community radiology practice after dedicated teaching courses: 2-year medical audit of 38,633 cases. Radiology (1992) 1.30
Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells. J Cell Physiol (1984) 1.29
Structure of the rat platelet factor 4 gene: a marker for megakaryocyte differentiation. Mol Cell Biol (1987) 1.29
Transcriptional regulation of the rat platelet factor 4 gene: interaction between an enhancer/silencer domain and the GATA site. Mol Cell Biol (1991) 1.28
Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation (1994) 1.28
Systematically missing confounders in individual participant data meta-analysis of observational cohort studies. Stat Med (2009) 1.27
The basic helix-loop-helix transcription factor capsulin controls spleen organogenesis. Proc Natl Acad Sci U S A (2000) 1.26
Enhancement of murine cardiac chronotropy by the molecular transfer of the human beta2 adrenergic receptor cDNA. J Clin Invest (1998) 1.25
Inhibition of human factor IXa by human antithrombin. J Biol Chem (1975) 1.25
Heparin with two binding sites for antithrombin or platelet factor 4. J Biol Chem (1982) 1.25
Selective targeting of gene products with the megakaryocyte platelet factor 4 promoter. Proc Natl Acad Sci U S A (1991) 1.24
Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1 + 2 fragment and thrombin--antithrombin complex. Blood (1982) 1.24
The effects of quality and timing of venepuncture on markers of blood coagulation in healthy middle-aged men. Thromb Haemost (1995) 1.23
6-O-sulfotransferase-1 represents a critical enzyme in the anticoagulant heparan sulfate biosynthetic pathway. J Biol Chem (2001) 1.23
Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. J Clin Invest (1981) 1.23
Endothelial expression of thrombomodulin is reversibly regulated by fluid shear stress. Circ Res (1994) 1.22
Human von Willebrand factor gene sequences target expression to a subpopulation of endothelial cells in transgenic mice. Proc Natl Acad Sci U S A (1995) 1.20
Expression cloning of LDLB, a gene essential for normal Golgi function and assembly of the ldlCp complex. Proc Natl Acad Sci U S A (1999) 1.20
Endothelium-specific loss of murine thrombomodulin disrupts the protein C anticoagulant pathway and causes juvenile-onset thrombosis. J Clin Invest (2001) 1.20
Isolation and characterization of heparan sulfate proteoglycans produced by cloned rat microvascular endothelial cells. J Biol Chem (1992) 1.20
Tumor necrosis factor enhances expression of tissue factor mRNA in endothelial cells. Thromb Res (1989) 1.19
Characterization of a thrombomodulin cDNA reveals structural similarity to the low density lipoprotein receptor. Proc Natl Acad Sci U S A (1986) 1.18
Patterns of mammography use among Hispanic, American Indian, and non-Hispanic White women in New Mexico, 1994-1997. Am J Epidemiol (2000) 1.18
Contribution of 3-O- and 6-O-sulfated glucosamine residues in the heparin-induced conformational change in antithrombin III. Biochemistry (1987) 1.18
Activation of human prothrombin by highly purified human factors V and X-a in presence of human antithrombin. J Biol Chem (1975) 1.16
Purification of heparan sulfate D-glucosaminyl 3-O-sulfotransferase. J Biol Chem (1996) 1.16
Detection of factor X activation in humans. Blood (1989) 1.15
PDGF mediates cardiac microvascular communication. J Clin Invest (1998) 1.15
Molecular cloning and characterization of a human uronyl 2-sulfotransferase that sulfates iduronyl and glucuronyl residues in dermatan/chondroitin sulfate. J Biol Chem (1999) 1.15
Antisense nonmuscle myosin heavy chain and c-myb oligonucleotides suppress smooth muscle cell proliferation in vitro. Circ Res (1992) 1.14
The effect of precursor structures on the action of glucosaminyl 3-O-sulfotransferase-1 and the biosynthesis of anticoagulant heparan sulfate. J Biol Chem (2001) 1.14
Increased activation of the haemostatic system in men at high risk of fatal coronary heart disease. Thromb Haemost (1996) 1.14
Molecular enhancement of porcine cardiac chronotropy. Heart (2001) 1.13
Aggressive angiomyxoma of the female pelvis and perineum: review of the literature. Gynecol Oncol (1991) 1.13
The role of syndecan cytoplasmic domain in basic fibroblast growth factor-dependent signal transduction. J Biol Chem (1999) 1.13
Characterization of ryudocan glycosaminoglycan acceptor sites. J Biol Chem (1994) 1.13
Heparin prevents vascular smooth muscle cell progression through the G1 phase of the cell cycle. J Biol Chem (1989) 1.13
Factor IX is activated in vivo by the tissue factor mechanism. Blood (1990) 1.13
Sequence variation in heparin octasaccharides with high affinity for antithrombin III. Biochemistry (1984) 1.12
Transforming growth factor-beta 1-mediated inhibition of the flk-1/KDR gene is mediated by a 5'-untranslated region palindromic GATA site. J Biol Chem (2000) 1.11
Human thrombomodulin gene is intron depleted: nucleic acid sequences of the cDNA and gene predict protein structure and suggest sites of regulatory control. Proc Natl Acad Sci U S A (1987) 1.11